C1orf168 Inhibitors
C1orf168 inhibitors comprise a spectrum of chemical entities that directly or indirectly lead to the diminishment of C1orf168's functional activity by interfering with specific intracellular signaling cascades. Wortmannin and LY 294002, both PI3K inhibitors, obstruct the PI3K/AKT/mTOR pathway, which is pivotal for numerous cellular processes including growth, survival, and proliferation. If C1orf168 is implicated in this pathway, the inhibition of PI3K would prevent the activation of AKT and subsequent signaling, leading to reduced C1orf168 activity. Rapamycin, targeting mTOR, would have a similar inhibitory effect on C1orf168 if it is mTORC1-dependent. The MAPK pathway, another crucial signaling network, can be modulated by the selective inhibition of its components, such as p38 MAPK by SB 203580, MEK1/2 by PD 98059 and U0126, and JNK by SP600125. Inhibition of these MAPK pathway components could result in the functional suppression of C1orf168 if it is a downstream effector, curtailing its activity by impeding necessary phosphorylation events.
Furthermore, the Src family kinase signaling, which plays a significant role in controlling various cellular functions including migration, invasion, and proliferation, can be inhibited by Dasatinib and PP 2, suggesting that if C1orf168 operates downstream of Src kinase signaling, these inhibitors would lead to a decrease in its activity. The RhoA/ROCK pathway, which is targeted by Y-27632, a ROCK inhibitor, could also implicate a reduction in C1orf168 activity if it is involved in the RhoA/ROCK signaling. Lastly, Gefitinib and Triciribine, which inhibit EGFR and AKT respectively, could lead to diminished C1orf168 function if C1orf168 is involved in the EGFR pathway or is regulated by AKT-dependent phosphorylation. The specific biochemical interaction between C1orf168 and these signaling pathways underscores the intricate regulatory mechanisms that govern cellular homeostasis and the potential of these inhibitors to impact C1orf168's role within these pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that impedes the PI3K/AKT/mTOR pathway. C1orf168, when involved in this pathway, would have its activity diminished due to the decreased signaling through AKT, which is crucial for the function of many proteins involved in survival and growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor that blocks the PI3K/AKT signaling pathway. By inhibiting PI3K, LY2 94002 reduces AKT phosphorylation and activation leading to a subsequent decrease in C1orf168 activity if it is downstream of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which acts specifically on the mTORC1 complex, leading to the inhibition of downstream proteins that rely on mTORC1 signaling for activation. If C1orf168 functions downstream of mTORC1, its activity would be diminished by rapamycin. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK. If C1orf168's function is modulated by p38 MAPK signaling, SB 203580 would lead to its functional inhibition by blocking this specific MAPK pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor which blocks the MEK1/2-ERK1/2 signaling pathway. C1orf168, if functioning downstream of this pathway, would have reduced activity due to the inhibition of MEK1/2 and the subsequent reduction in ERK1/2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK pathway. By inhibiting JNK signaling, SP600125 could diminish C1orf168's activity if it is regulated by JNK-mediated phosphorylation events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor that would diminish C1orf168 activity if it is associated with signaling pathways involving Src kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
An Src family kinase inhibitor that prevents Src-mediated activation of downstream targets. If C1orf168 relies on Src signaling, PP 2 would reduce its activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that would lead to decreased C1orf168 activity if C1orf168 is a downstream effector in the RhoA/ROCK pathway. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR tyrosine kinase inhibitor that, by inhibiting EGFR signaling, could diminish C1orf168 activity if C1orf168 operates downstream of the EGFR pathway. | ||||||